HIM
CNCE

Hillsdale Investment Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Hillsdale Investment Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-8,400
Closed -$143K – 540
2017
Q1 		$143K Buy
+8,400
New +$101K 0.03% 292

Other funds holding CNCE

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM

Hillsdale Investment Management's CNCE Position: Q2 2017 in Review

Hillsdale Investment Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2017, closing a stake of 8,400 shares — an estimated $143K sold.

Hillsdale Investment Management first reported a position in CNCE in Q1 2017 and held it in 1 quarter. The position peaked at $143K in Q1 2017. 79 funds tracked by Wall St. Rank hold CNCE as of Q2 2017.

  • Hillsdale Investment Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Hillsdale Investment Management sold 8,400 Concert Pharmaceuticals, Inc. shares in Q2 2017, an estimated $143K.
  • Hillsdale Investment Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • Hillsdale Investment Management's Concert Pharmaceuticals, Inc. position peaked at $143K in Q1 2017.
  • 79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2017.

Based on Hillsdale Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.